NCT04594772 is a Phase 2 clinical trial of Folfirinox in Pancreas Cancer, sponsored by University of Cincinnati.

Who is sponsoring NCT04594772?

NCT04594772 is sponsored by University of Cincinnati.

What drugs are being tested in NCT04594772?

Interventions in NCT04594772: Folfirinox, Gemcitabine, radiation therapy, Pancreatectomy.

What condition does NCT04594772 study?

NCT04594772 studies Pancreas Cancer.

Is NCT04594772 still recruiting?

NCT04594772 is currently active, enrolled. Last updated 2 July 2025.

Last reviewed 2025-07-02 · How we verify

NCT04594772

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Adaptive Approach to Neoadjuvant Therapy to Maximize Resection Rates for Pancreatic Adenocarcinoma

Active, enrolled Phase 2 Last updated 2 July 2025

What this trial tests

Phase 2 trial testing Folfirinox in Pancreas Cancer in 32 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

17 March 2021

Primary endpoint
13 June 2025

1 January 2026

Quick facts

Lead sponsor	University of Cincinnati
Phase	Phase 2
Status	Active, enrolled
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	32
Start date	17 March 2021
Primary completion	13 June 2025
Estimated completion	1 January 2026
Sites	2 locations across United States

Drugs / interventions tested

Folfirinox (folfirinox) — full drug profile →
Gemcitabine (gemcitabine) — full drug profile →
radiation therapy — full drug profile →
Pancreatectomy

Conditions studied

Pancreas Cancer — all drugs for Pancreas Cancer →

Sponsor

University of Cincinnati

Who can join

18 and older, any sex, with Pancreas Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to determine if neoadjuvant therapy to increases resection rate for pancreatic adenocarcinoma.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

The evolving role of radiation in pancreatic cancer.
Malla M, Fekrmandi F, Malik N, Hatoum H, et al · · 2022 · cited 12× · PMID 36713520 · DOI 10.3389/fonc.2022.1060885
Evolving concepts in adjuvant/neoadjuvant therapy for resectable pancreas cancer.
Bryant JM, Ruffolo L, Soares K, Hoffe S, et al · · 2025 · cited 4× · PMID 40662364 · DOI 10.1172/jci191944

Verify or expand the search:

Other trials of Folfirinox

Trials testing the same drug.

NCT07340567 — Personalizing Chemotherapy Selection After Surgery for Patients With Stage III Colorectal Cancer Using a Blood Test · Phase 3 · not yet recruiting
NCT06068023 — The ADAPTA Study: ADjuvant chemotherAPy After Curative Intent resecTion of Ampullary Cancer. · recruiting
NCT05132504 — Neoadjuvant Folfirinox Combined With Pembrolizumab Followed by Surgery for Patients With Resectable Pancreatic Cancer · Phase 2 · recruiting
NCT04431258 — ABTL0812 in Combination With FOLFIRINOX for First-line Treatment of Metastatic Pancreatic Study · Phase 1, PHASE2 · completed
NCT04897854 — Timing of Start of systemIc Treatment for Asymptomatic Metastasized Pancreatic Cancer · Phase 3 · unknown

Other recruiting trials for Pancreas Cancer

Currently open trials in the same condition.

NCT07126158 — Stereotactic Body Radiotherapy Plus FAK and RAF/MEK Inhibition in Advanced Pancreatic Adenocarcinoma · Phase 2 · recruiting
NCT07230509 — Pancreatic Parenchymal Injection of N-butyl-2-cyanoacrylate · Phase 2 · recruiting
NCT06926075 — Early Phase Study of KESONOTIDE™in Participants With Solid Tumours · Phase 1, PHASE2 · recruiting
NCT07179692 — CEA-Targeted CAR-T Therapy in CEA-Positive Advanced Solid Tumors · Phase 1 · recruiting
NCT07132541 — Saleh's Technique for Pancreaticojejunostomy (Pancreatic Parenchymal Injection of N-butyl-2-cyanoacrylate) · Phase 1 · recruiting

Other University of Cincinnati trials

Trials by the same sponsor.

NCT05605366 — Minocycline In Neurocognitive Outcomes - Sickle Cell Disease · Phase 1 · not yet recruiting
NCT07528638 — Intraoperative Neuromonitoring (IONM) and Bipolar Electrocautery (BE) During Axillary Lymph Node Dissection (ALND) · NA · not yet recruiting
NCT07494890 — Measurement Properties of Mechanical Cost of Walking for Individuals With Walking Impairment · NA · recruiting
NCT07447895 — Early Pelvic Floor Physical Therapy for Women Undergoing Pelvic Radiation for Gynecologic Malignancies · NA · not yet recruiting
NCT07231588 — Oral 5 Strain Probiotic for GI Toxicity Mitigation During Pelvic Radiation · EARLY_PHASE1 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04594772 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Cincinnati
Last refreshed: 2 July 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04594772.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing